U.S. puts Canada on watch list over drug-patent policy

05/7/2013 | Financial Post (Canada)

The Office of the U.S. Trade Representative expressed concern over Canada's treatment of pharmaceutical patents in a newly issued report on intellectual-property issues. The trade office placed Canada on its watch list for issues relating to the lack of appeal rights for innovative companies and heightened utility requirements that may violate trade agreements.

View Full Article in:

Financial Post (Canada)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL